QUICK, SIMPLE, SCALABLE
WHEN PROTEINS MATTER
Biopharmaceutical proteins including monoclonal antibodies, vaccine, therapeutic enzymes are the next blockbuster products of pharma industries. Current mammalian cell-based platform have an issue of scalability and time-consuming from research scale to industrial scale production. It is also not versatile to a changing disease trends, outbreaks and pandemic. Even the high investment in research and development of new medicine, only 10% went through Phase I clinical trials were approved by the FDA. Multinational pharmaceutical companies focus on diseases with high prevalence, many patients with some diseases are left with no access to treatment. This market is even though considered as niche however, high value market.
Baiya’s phytopharm’s plant-based technology is a cutting-edge solutions that is quick, simple and scalable aiming to replace biotech’s fermenter with plants. The platform has the flexibility to produce biopharmaceutical products of interest within weeks rather than months or years which resulted in a faster and lower cost of research and development.
BASIC FIBROBLAST GROWTH FACTOR
the raw material for cosmetic production with the anti-aging purpose. the mechanism of action is straight through the human cell to promote the proliferation process of collagen in the epidermis to strength up our skin and fade the wrinkles away. we extract freshly from our transient plant and purify to ensure the good quality for cosmetic production.
CSO and Co-founder
Lecturer, Pharmacognosy and Pharmaceutical Botany, Faculty of Pharmaceutical Sciences, chulalongkorn University - Feb 2011 – Apr 2014
Newton International Fellow, St. George\'s Medical School, University of London - May 2014 – Apr 2016
Assistant Professor, Pharmacognosy and Pharmaceutical Botany, Faculty of Pharmaceutical Sciences, chulalongkorn University - May 2014 – Apr 2018
Associate Professor, Pharmacognosy and Pharmaceutical Botany, Faculty of Pharmaceutical Sciences, chulalongkorn University - Apr 2018 – Present
1. Shanmugaraj B, Siriwattananon K, Wangkanont K, Phoolcharoen W. Perspective on monoclonal antibody therapy as potential therapeutic intervention for Coronavirus diseases-19 (COVID-19). Asian Pac J Allergy Immunol. 2020
2. Shanmugaraj B, Malla A, Phoolcharoen W. Emergence of Novel Coronavirus 2019-nCoV: Need for rapid vaccine and biologics development. Pathogens. 2020; 9(2): pii: E148. doi: 10.3390/pathogens9020148. Review.
3. Klinthoopthamrong N, Chaikiawkeaw D, Phoolcharoen W, Rattanapisit K, Kaewpungsup P, Pavasant P, Hoven P. Bacterial cellulose membrane conjugated with plant-derived osteoponint: Preparation and its potential for bone tissue regeneration. Int J Biol MAcromol. 2020; 22: 149-151.
4. Ahmad AR, Kaewpungsup P, Khorattanakul N, Rattanapisit K, Pavasant P, Phoolcharoen W. Recombinant human dentin matrix protein 1 (hDMP1) expressed in Nicotiana benthamiana potentially induces isteogenic differentiation. Plants (Basel). 2019; doi: 10.3390/plants8120566.
5. Rattanapisit K, Chao Z, Siriwattananon K, Huang Z, Phoolcharoen W. Plant-produced antienterovirus 71 (EV71) monoclonal antibody efficiently protects mice against EV71 infection. Plants (Basel). 2019; doi: 10.3390/plants8120560.
6. Murad S, Fuller S, Menary J, Moore C, Pinneh E, Szeto T, Hitzeroth I, Freire M, Taychakhoonavudh S, Phoolcharoen W, Ma JK. Molecular pharming for low and middle income countries. Curr Opin Biotechnol. 2019; 61: 53-59.
CEO and Co-founder
EDUCATION WORK EXPERIENCE.